Applied Genetic Technologies Corp. (AGTC) plans to launch a pivotal trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) by the end of this year, following strong positive six-month data from its ongoing Phase I/II trial. Normal retina pictured at left; retina affected by retinitis pigmentosa pictured at right. [AGTC]
Applied Genetic Technologies Corp. (AGTC) plans to launch a pivotal trial of its gene therapy candidate for X-linked retinitis pigmentosa (XLRP) by the end of this year, following strong positive six-month data from its ongoing Phase I/II trial . . .
See More on the Edge
Continue reading this article and more
with a GEN Edge subscription
